Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment

Like
Comment
Favorite

Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment

MT Newswires Live03-03

Voyager Therapeutics (VYGR) reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.

Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.

The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.

Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography (PET) imaging data in H2 2026.

Voyager shares were down nearly 3% in recent trading.

Price: 3.97, Change: -0.11, Percent Change: -2.70

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

19:07
Heathrow Chairman Regrets Disruption Caused by Power Outage, Orders Former Transport Secretary Ruth Kelly to Undertake Internal Review
16:20
Reliance Discussed Selling Data Center Capacity to OpenAI and Meta - the Information
16:20
OpenAI Discussed Cutting Chatgpt Subscription Price Between 75% and 85% in India - the Information
16:20
OpenAI and Meta Seek AI Alliance With India’s Reliance - the Information
15:25
Britain's Energy Minister Commissions National Energy System Operator to Urgently Investigate Power Outage That Impacted Heathrow Airport and Surrounding Area, Government Says

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2516657210?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-04 03:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516657210","market":"fut","top_or_hot":-1,"title":"Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment","media":"MT Newswires Live","content":"<html><body><p> Voyager <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VYGR) reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.</p><p>Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.</p><p>The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.</p><p>Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography (PET) imaging data in H2 2026.</p><p>Voyager shares were down nearly 3% in recent trading.</p><p>Price: 3.97, Change: -0.11, Percent Change: -2.70</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVoyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-04 03:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Voyager <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VYGR) reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.</p><p>Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.</p><p>The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.</p><p>Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography (PET) imaging data in H2 2026.</p><p>Voyager shares were down nearly 3% in recent trading.</p><p>Price: 3.97, Change: -0.11, Percent Change: -2.70</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PET.AU","symbol_name":"Phoslock Environmental","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516657210","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516657210","pubTimestamp":1741030053,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Voyager Therapeutics  reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography  imaging data in H2 2026.Voyager shares were down nearly 3% in recent trading.Price: 3.97, Change: -0.11, Percent Change: -2.70","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PET.AU":"Phoslock Environmental","BK4139":"生物科技","VYGR":"Voyager Therapeutics Inc","BK4192":"特殊消费者服务","PET":"Wag! Group Co","BK7047":"环境与设施服务"},"translate_title":"Voyager Therapeutics报告阿尔茨海默病治疗的积极试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PET":1,"PET.AU":1,"VYGR":1},"content_text":"Voyager Therapeutics (VYGR) reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography (PET) imaging data in H2 2026.Voyager shares were down nearly 3% in recent trading.Price: 3.97, Change: -0.11, Percent Change: -2.70","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}